Parkinson's Disease (PD) Clinical Trial
Official title:
An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinson's Disease
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how safe and effective ABBV-951 is in adult participants with PD. Adverse events and change in disease activity is evaluated. ABBV-951 is an investigational (unapproved) drug containing Levodopa Phosphate/Carbidopa Phosphate (LDP/CDP) given as an infusion under the skin for the treatment of Parkinson's Disease. Adult participants with advanced PD and who have completed M15-736 or M20-339 study will be enrolled. Approximately 130 participants will be enrolled in the study in approximately 60 sites in the United States and Australia. Participants will receive continuous subcutaneous infusion (CSCI) (under the skin) of ABBV-951 for 96 weeks during the Primary Treatment Period and during the optional Extended Treatment Period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical and remote telephone assessments, blood tests, checking for side effects, and completing questionnaires.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02170376 -
The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT02169895 -
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide
|
Phase 1 | |
| Completed |
NCT02169479 -
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa
|
Phase 1 | |
| Completed |
NCT02778594 -
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide
|
Phase 1 | |
| Completed |
NCT02274766 -
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
|
Phase 3 | |
| Completed |
NCT02169453 -
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa
|
Phase 1 | |
| Completed |
NCT04380142 -
Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease
|
Phase 3 | |
| Withdrawn |
NCT06118294 -
Efficacy of Probiotics for Parkinson Disease (PD)
|
N/A | |
| Recruiting |
NCT05916157 -
An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease
|
||
| Completed |
NCT03033498 -
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease
|
Phase 1 | |
| Completed |
NCT02169427 -
An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites
|
Phase 1 | |
| Completed |
NCT02834507 -
Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients
|
Phase 2 | |
| Active, not recruiting |
NCT04379050 -
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
|
Phase 3 | |
| Completed |
NCT02169440 -
Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin
|
Phase 1 | |
| Completed |
NCT02202551 -
Open-Label Safety Study of ADS-5102 in PD Patients With LID
|
Phase 3 | |
| Completed |
NCT01398748 -
Intranasal Glutathione in Parkinson's Disease
|
Phase 1 | |
| Recruiting |
NCT06107426 -
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
|
||
| Completed |
NCT02169466 -
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide
|
Phase 1 | |
| Recruiting |
NCT03732898 -
Coordinated Reset Deep Brain Stimulation
|
N/A | |
| Completed |
NCT02799381 -
A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)
|
Phase 3 |